Paige

What Paige does

Paige is a New York-based AI company that builds software for cancer pathology, founded in 2017 (per company history) by Thomas Fuchs of Memorial Sloan Kettering and operating as Paige.AI, Inc. Its core technology is a series of proprietary pathology foundation models — Virchow (632M parameters), Virchow2 and Virchow2G (1.8B parameters each), and the multimodal PRISM/PRISM2 — trained on more than 3 million digitized pathology slides from over 800 laboratories across 45 countries and 225,000+ patients, with access to a broader pool of ~25 million slides. On top of these models Paige delivers tissue-specific diagnostic suites (Paige Prostate Suite, Breast Suite, GI Suite, PanCancer Suite), the FDA-cleared FullFocus whole-slide image viewer, the OmniScreen biomarker prescreening tool that simulates 1,600 cancer biomarkers, and Paige Alba, a multi-modal AI co-pilot with voice and text commands for pathology workflows.

Paige sells primarily through enterprise SaaS subscription licensing with annual, quote-based pricing, distributed via direct enterprise sales teams and channel partners including Sectra, Epredia, and OptraSCAN. The customer base spans hospital systems and academic medical centers (e.g., Ohio State Wexner, University Medical Center Utrecht, NHS Wales, Burjeel Holdings, Grupo Oncoclinicas, University of Florida Jacksonville) and pharmaceutical/life sciences organizations using Paige's AI for biomarker discovery, companion diagnostics, and clinical trial design. The company holds the first FDA De Novo authorization for AI in digital pathology (2021), FDA Breakthrough Device Designation, multiple 510(k) clearances, and CE-IVD/UKCA marks for products marketed in Europe and the UK.

As of August 2025, Paige was acquired by Tempus AI for $81.25 million (predominantly in Tempus common stock plus assumption of Paige's Microsoft Azure cloud agreement), ending its status as an independent entity and positioning Paige's foundation models, dataset, and team inside Tempus's larger precision-medicine platform.

Name

Paige

Legal name

Paige.AI, Inc.

Website

https://paige.ai

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

51–100 employees

Short description

Paige develops AI foundation models and clinical-grade applications for cancer pathology diagnostics and biomarker discovery, serving hospital systems and pharmaceutical clients with FDA-authorized diagnostic suites and the Alba co-pilot.

Ownership category

akta.pro rank

Product category

Digital Pathology AI Software

NAICS

Software Publishers (513210), Medical and Diagnostic Laboratories (62151)

SIC

Services-Prepackaged Software (7372), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

Keywords

• Digital pathology AI
• Cancer diagnostic software
• Computational pathology
• Biomarker discovery AI
• Foundation model pathology

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Infrastructure, Operations

Revenue model

1. SaaS Subscription Licensing: Software-as-a-service subscription licensing model providing access to AI-powered pathology diagnostic tools on a recurring basis.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Paige develops AI-powered clinical software for cancer pathology, including tissue-specific diagnostic suites (Prostate, Breast, GI), a pan-cancer detection suite, the FDA-cleared FullFocus whole-slide image viewer, the biomarker screening tool OmniScreen, and the Paige Alba AI co-pilot. The portfolio is built on proprietary foundation models (Virchow, Virchow2, Virchow2G, PRISM2) trained on more than 3 million digitized pathology slides and is sold as enterprise subscriptions to clinical laboratories and licensed to pharmaceutical and life-sciences partners.

Product overview

Paige offers a comprehensive platform of clinical AI applications for cancer diagnostics built on proprietary foundation models and a vast digital pathology dataset of over 25 million accessible pathology slides from 350,000 patients across 45 countries. The portfolio includes diagnostic AI suites for specific tissue types (Prostate Suite, Breast Suite, GI Suite) and pan-cancer detection (PanCancer Suite), alongside the AI co-pilot Alba, the FDA-cleared FullFocus whole-slide image viewer, and OmniScreen for biomarker screening. The platform also provides foundation models (Virchow, Virchow2, Virchow2G, PRISM2) available for licensing and custom AI development services for pharmaceutical and life sciences partners. Paige's technology enables cancer detection, grading, biomarker prediction, and precision medicine workflows across clinical practice and drug development.

Differentiator

Problem solved

Functional benefit

Brands

• Paige Prostate Suite: AI applications for detecting and diagnosing prostate cancer on H&E-stained whole-slide images
• Paige Breast Suite
• Paige GI Suite
• Paige PanCancer Suite
• FullFocus
• Paige Alba
• Virchow
• Virchow2
• Virchow2G
• PRISM
• PRISM2
• OmniScreen
• Paige Colon MSI

Products and services

• Paige Prostate Suite Comprehensive AI applications that aid detection and diagnosis of prostate cancer on H&E-stained whole-slide images of prostate needle biopsies, including cancer detection, Gleason pattern grading, tumor quantification, and perineural invasion identification, for clinical pathology laboratories.
• Paige Breast Suite AI applications that support pathologists in identifying and classifying breast cancer on H&E-stained whole-slide images from breast biopsy and excision specimens, including lymph node metastasis detection and mitotic counting.
• Paige GI Suite Portfolio of AI-powered applications supporting pathologists in detecting and classifying benign and malignant conditions across the entire gastrointestinal tract, built on Paige's latest foundation model technology.
• Paige PanCancer Suite AI applications developed using the Virchow foundation model and cumulatively trained on over 1.5 million slides to help pathologists identify cancer across multiple tissue types including rare cancers and metastatic deposits.
• Paige Alba Proprietary multi-modal AI co-pilot that integrates Paige's diagnostic and foundation model technologies with voice and text commands to streamline pathologists' cancer detection and diagnosis workflows and provide real-time clinical insights.
• FullFocus FDA-cleared, CE-IVDR marked, and UKCA marked whole-slide image viewer that enables physicians to unlock digital pathology and AI's full potential, with diagnostic and collaboration tools, AI visualizations, and multi-scanner compatibility.
• OmniScreen AI tool that simultaneously screens 505 genes for comprehensive cancer diagnosis and personalized treatment selection by simulating a panel of 1,600 clinically significant cancer biomarkers from H&E-stained images, enabling rapid biomarker identification for therapeutic targeting and clinical trial design.
• Virchow Foundation Model Family (Virchow, Virchow2, Virchow2G, Virchow2G-Mini) Pathology foundation models with up to 1.8 billion parameters trained on 3+ million digitized slides across 800+ labs and 45 countries, providing general-purpose computational pathology capabilities for cancer detection, biomarker prediction, and custom AI development by Paige and its partners.
• PRISM2 Slide-level multimodal foundation model trained on over 2.3 million whole-slide images paired with clinical reports and integrated with Microsoft Phi-3, enabling diagnostic, biomarker prediction, and multi-modal patient outcome modeling through connection of visual patterns with clinical language.
• AI Technology & Services Comprehensive services offering Paige foundation models and AI modules for third-party partners, custom AI development, prognostic or predictive application development, regulatory strategy, and commercialization services for life sciences and pharmaceutical organizations.

Quantifiable outcome

• First FDA authorization for AI-assisted cancer detection in digital pathology
• +3 more outcomes

Named customers7 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration10 records

AI capability9 records

Feature5 records

Partnerships

13 partnerships are on record, tiered core, flagship and minor.

• MicrosoftcoreTechnology or IntegrationCollaboration on AI foundation models for cancer diagnosis, leveraging Microsoft's cloud and AI infrastructure to advance digital pathology capabilities.
• Leica BiosystemscoreStrategic or Co-development PartnerExpanded partnership for digital pathology workflows, integrating Paige AI with Leica's pathology instruments and systems.
• Breast International Group (BIG)coreStrategic or Co-development PartnerStrategic partnership for AI-driven breast cancer research, combining BIG's clinical research expertise with Paige's AI capabilities.
• Burjeel HoldingsflagshipStrategic or Co-development PartnerPartnership to deploy FDA-approved AI across MENA region, bringing AI-powered cancer diagnostics to healthcare facilities in the Middle East and North Africa.
• SectracoreChannel Partner/ Reseller/ DistributorDistribution agreement for Paige's AI applications through Sectra's digital pathology platform, expanding market reach in Europe and globally.
• EprediacoreChannel Partner/ Reseller/ DistributorGlobal commercial distribution agreement enabling Epredia to distribute Paige AI solutions alongside their pathology products worldwide.
• NHS Wales (Betsi Cadwaladr University Health Board)flagshipStrategic or Co-development PartnerPilot project for PanCancer Detect, implementing AI-powered cancer screening in NHS Wales healthcare facilities.
• University Medical Center UtrechtcoreStrategic or Co-development PartnerResearch partnership for CONFIDENT-P study, collaborating on clinical validation of AI for cancer diagnostics.
• University of YorkminorStrategic or Co-development PartnerAI safety program partnership focused on responsible development and deployment of AI in pathology.
• University of OxfordminorStrategic or Co-development PartnerResearch collaboration on patient perspectives regarding AI use in cancer diagnostics.
• Ohio State Wexner Medical CenterflagshipStrategic or Co-development PartnerCollaboration on AI tools development and clinical implementation for pathology diagnostics.
• University of Florida College of Medicine - JacksonvillecoreStrategic or Co-development PartnerAdoption and implementation of Paige AI for pathology diagnostics in academic medical center setting.
• OptraSCANminorChannel Partner/ Reseller/ DistributorPartnership to streamline digital pathology adoption through OptraSCAN's scanning and imaging solutions.

Scale indicators8 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• Owkin: Owkin applies AI to pathology and multimodal patient data for drug discovery and diagnostics. It targets overlapping pharma and clinical customers with foundation-model approaches similar to Paige's Virchow roadmap.
• PathAI: PathAI is a leading AI pathology company developing diagnostic and biomarker products on its AISight image management platform. It is the most direct competitor to Paige, offering overlapping cancer detection AI and integrating Paige's own products alongside its own algorithms.
• Ibex Medical Analytics: Ibex develops AI-powered cancer diagnostics for pathology, with FDA-cleared products for breast and prostate cancer detection. It competes head-to-head with Paige's Prostate and Breast Suites across enterprise pathology customers.
• Proscia: Proscia offers a digital pathology platform with AI applications for cancer diagnosis and biomarker quantification. It competes with Paige's FullFocus viewer and diagnostic AI suites across research and clinical labs.
• Aiforia: Aiforia provides AI image analysis solutions for pathology, including cancer detection and grading. Paige has an active integration partnership with Aiforia, and the two compete in AI-assisted clinical diagnostics.
• Deep Bio: Deep Bio develops AI for prostate cancer pathology and is integrated into PathAI's AISight alongside Paige's prostate products. It is a focused direct competitor in Paige's flagship prostate suite category.
• Mindpeak: Mindpeak builds AI tools for cancer diagnosis in pathology and has a joint integration partnership with Paige. Both companies offer complementary AI applications across the same clinical pathology customer base.
• Visiopharm: Visiopharm provides AI-driven image analysis for digital pathology, including cancer diagnostics and research applications. Its products are integrated into PathAI AISight alongside Paige's, positioning it as a direct peer in the same deployment ecosystem.

Broad incumbents

• Philips (Digital Pathology): Philips is a major incumbent in digital pathology scanners and workflow software. Its Ultrafast Scanner is part of Paige's FullFocus compatibility ecosystem, and its broader healthcare AI portfolio overlaps with Paige's clinical ambitions.
• Roche (Digital Pathology): Roche's digital pathology division offers whole-slide imaging, image management, and AI workflow tools as part of its broader diagnostics portfolio. It competes with Paige on enterprise pathology platforms while also partnering across the broader oncology ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/paige_ai
• LinkedInlinkedin.com/company/paige-ai

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Paige